Thank you generactor. I appreciate this post. As
Post# of 148277
Aside from his credentials and from his youth, what hit me most about your post, is what you put in parentheses:
Quote:
(from now on we'll be a regular boring pharma as far as PR goes)
and it appears to be quite clear that Cyrus operates as such.
However, the press releases that Leronlimab is capable of generating will not be boring, but the exuberant, raving and ravishing press releases on the possibilities of this or on the announcement of that, now are a long lost thing of the past which will no longer will be practiced by this administration and for very good reason and I'm one completely for that.
It is my hope this will garner a new found level of respect for the company, for what it says, for what it stands for, and for what it does in its strengthened efforts on eradicating itself from the depths of difficulty it had dug itself into. I suspect that with our new team led by this man, we will find our selves quickly leaping, escalating and exiting out of this hole, surprisingly clothed with a clean 3 piece suit, rising to our feet, upright, pen in hand, ready to do business.
Yes, the reclamation project is underway and we remain beneath the Earth, but those walls are no longer caving in on us and building blocks are in place to keep them from caving. They are no longer slippery so we keep sliding down, but rather, we have learned to climb them and ascend them and soon we will be out. And this is only being done by the team we have in place. What is happening there, is respectable and honorable.
I also appreciate your recap of the recent run up in share price. I like your idea of it being a bit of a short squeeze even causing short interest rate to exceed 100% for a few days. But, if it were a short squeeze, they were successful in keeping it to a minimum. If it truly was a short squeeze, there were some initial investors that had those huge buys of 250,000 shares, 300, 400, 500 thousand shares for 1-2 weeks and then it all stopped. There was no follow through. Maybe those huge buyers were the ones who sold at $1.20 and shorted it down? Maybe not. Maybe they are down on their buys at $1.20? Regardless, if it was a short squeeze, there was no news to back it on. There was no follow through and so the shorts were able to counter the squeeze regardless of the cost to borrow because the squeeze did not last nor did it rise to sufficient levels to make them cover. I think if prices had risen to say $3 or $4 for a month or two, they would have caved completely and prices would have risen to even $10 by their covering, but Leronlimab will bring about a coming Press Release that will do that even if the shorts all simultaneously all doubled down and shorted the stock till they were blue in the face.
I think we have to face the fact that shorts aren't going anywhere and they are part of this, but they are learning that it's no longer going to be easy pickins.